A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Clinical Trial in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Treated With Fruquintinib
Phase of Trial: Phase III
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Fruquintinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms FALUCA
- Sponsors Chi-Med; Hutchison MediPharma
- 31 Jul 2017 According to a Chi-Med media release company expects to complete FALUCA enrollment in early 2018 and and top-line data expected in late 2018.
- 03 Mar 2017 Topline results from the FALUCA study are expected to be released in early 2018, according to a Hutchison MediPharma media release.
- 02 Aug 2016 According to a Chi-Med media release, company expects to complete FALUCA enrollment in early 2017 and reach overall survival endpoint maturity in late 2017.